New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - anastrozole 1mg - film coated tablet - 1 mg - active: anastrozole 1mg excipient: hypromellose lactose monohydrate magnesium stearate opadry white y-1-7000 povidone sodium starch glycolate - treatment of advanced breast cancer in post-menopausal women.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - sodium cromoglicate 100mg;  ;  ;  ;   - capsule - 100 mg - active: sodium cromoglicate 100mg         excipient: gelatin black ink 1014/ sw-9008 - for chronic inflammatory conditions such as proctitis, ulcerative colitis and proctocolitis, and for use in the treatment of food allergic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - tamsulosin hydrochloride 0.4mg - capsule - 0.4 mg - active: tamsulosin hydrochloride 0.4mg excipient: brilliant blue fcf   carmoisine gelatin   talc (extragranular ingredients) ink iron oxide yellow magnesium stearate methacrylic acid - ethyl acrylate copolymer   microcrystalline cellulose ponceau 4r purified talc quinoline yellow sodium hydroxide sunset yellow fcf titanium dioxide     triacetin

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 50 mg/ml;  ;   - oral suspension - 50 mg/ml - active: clozapine 50 mg/ml     excipient: glycerol hydrochloric acid monobasic sodium phosphate dihydrate povidone purified water sodium hydroxide sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate sorbitol xanthan gum - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 200mg;   - tablet - 200 mg - active: clozapine 200mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - diltiazem hydrochloride 30mg;  ;  ;  ;   - film coated tablet - 30 mg - active: diltiazem hydrochloride 30mg         excipient: aluminium hydroxide gel hydrogenated castor oil lactose monohydrate magnesium stearate methacrylic acid copolymer opadry white y-1r-7000b purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - diltiazem hydrochloride 60mg;  ;  ;  ;   - film coated tablet - 60 mg - active: diltiazem hydrochloride 60mg         excipient: aluminium hydroxide gel hydrogenated castor oil lactose monohydrate magnesium stearate methacrylic acid copolymer opadry white y-1r-7000b purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fexofenadine hydrochloride 120mg; fexofenadine hydrochloride 120mg - film coated tablet - 120 mg - active: fexofenadine hydrochloride 120mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-8152hv povidone purified talc purified water titanium dioxide active: fexofenadine hydrochloride 120mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-27794 povidone purified talc purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fexofenadine hydrochloride 180mg; fexofenadine hydrochloride 180mg - film coated tablet - 180 mg - active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-8152hv povidone purified talc purified water titanium dioxide active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-27794 povidone purified talc purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.